Compare Neurocrine Biosciences Inc (NBIX) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Suncor Energy Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Suncor Energy Inc. trades at $69.27 (market cap $79.39B). The key difference: Suncor Energy Inc. is far larger — about 5× Neurocrine Biosciences Inc's market cap, and Suncor Energy Inc. pays a 2.55% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SU | |
|---|---|---|
Market Cap | $15.77B | $79.39B |
Sector | Health | Energy |
52-Week High | $185.50 | $69.73 |
52-Week Low | $123.10 | $38.17 |
Enterprise Value | $15.78B | $86.13B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Suncor Energy (SU) trades at $67.89, up 0.83% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.54 and net income margin of 14.7%, supported by Q2 2026 earnings beating estimates. Recent news highlights leadership transition to Peter Zebedee as CEO in 2027 and a dividend declaration of $0.60 per share payable September 25, 2026.
Outlook remains positive due to robust cash flow and buyback increases, but risks include commodity price volatility and operational challenges from weather events. Analyst consensus is strongly bullish with 74% buy ratings, indicating confidence in sustained performance amid energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
